Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inder Anand

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|May 24, 2012
The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspneaAlan H B Wu, Jeffrey Tabas, Johnathan Stein, et al.
American Heart Journal|June 18, 2018
High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trialOrly Vardeny, Jacob A Udell, Jacob Joseph, et al.
Emergency Medicine Journal : EMJ|September 11, 2012
Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trialMartin Möckel, Julia Searle, Oliver Hartmann, et al.
The Journal of Physiology|April 27, 2016
Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeuticsKalyanam Shivkumar, Olujimi A Ajijola, Inder Anand, et al.
Journal of the American College of Cardiology|August 27, 2011
Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trialAlan Maisel, Christian Mueller, Richard M Nowak, et al.
ESC Heart Failure|April 1, 2018
Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fractionVera J Goh, Jasper Tromp, Tiew-Hwa K Teng, et al.
Journal of the American College of Cardiology|July 5, 2023
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart FailureKieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
Circulation|November 19, 2019
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart FailureScott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|March 7, 2023
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HFDavid E Lanfear, Joyce N Njoroge, Kirkwood F Adams, et al.
JACC. Heart Failure|March 15, 2025
Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Exploratory Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialKieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|May 24, 2012
The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspneaAlan H B Wu, Jeffrey Tabas, Johnathan Stein, et al.
American Heart Journal|June 18, 2018
High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trialOrly Vardeny, Jacob A Udell, Jacob Joseph, et al.
Emergency Medicine Journal : EMJ|September 11, 2012
Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trialMartin Möckel, Julia Searle, Oliver Hartmann, et al.
The Journal of Physiology|April 27, 2016
Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeuticsKalyanam Shivkumar, Olujimi A Ajijola, Inder Anand, et al.
Journal of the American College of Cardiology|August 27, 2011
Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trialAlan Maisel, Christian Mueller, Richard M Nowak, et al.
ESC Heart Failure|April 1, 2018
Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fractionVera J Goh, Jasper Tromp, Tiew-Hwa K Teng, et al.
Journal of the American College of Cardiology|July 5, 2023
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart FailureKieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
Circulation|November 19, 2019
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart FailureScott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|March 7, 2023
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HFDavid E Lanfear, Joyce N Njoroge, Kirkwood F Adams, et al.
JACC. Heart Failure|March 15, 2025
Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Exploratory Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialKieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
Pageof 11